AzTrials
AzTrials

Muscular Dystrophy, BeckerWEST-DBMDNCT07511920

A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese Children

An observational study of Muscular Dystrophy, Becker and Muscular Dystrophy, run by West China Second University Hospital at 1 site in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This is a prospective, multicenter, longitudinal observational cohort study aimed at understanding the progression of Duchenne Muscular Dystrophy (DMD). The primary objective is to identify and integrate key biomarkers from multiple sources-including motor function assessments, body composition (muscle and fat… Read more about this study

Who is it for?
Ages 1 year to 18 years, men only
How many people
500 participants
Where
1 siteChina
Study dates
20 Apr 2026to 31 Dec 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 18 years
  • Men only
  • Child, Adult

Study population: This is a multicenter observational natural history study of male children and adolescents with genetically confirmed Duchenne or Becker Muscular Dystrophy. Participants will be followed longitudinally to document the natural progression of muscle weakness, functional decline, and associated comorbidities. The study population includes individuals across a range of disease severity and ages, from early childhood to late adolescence.

Who may be able to join

  • Male participants with genetically confirmed diagnosis of Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD)
  • Age range: 1 to 18 years old (adjust to your actual age limit)
  • Ability to complete study assessments and follow-up visits
  • Participants or legal guardians provide written informed consent

Who cannot join

  • Participants with other neuromuscular disorders that may confound natural history data
  • Participation in another interventional clinical trial that could affect disease progression
  • Severe comorbidities that prevent completion of study assessments
  • Inability to provide informed consent or comply with study procedures

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

China1 site
  • West China Second University Hospital, Sichuan University

    Chengdu

    Xiaotang Cai, Degree(学位 / 职称), +86 181 8060 9237, cxt_1999@126.com

Other trials in China

About this study

Official title: A Real-World, Multicenter Cohort Study on the Natural History of Duchenne and Becker Muscular Dystrophy in Children From Western China

This is a prospective, multicenter, longitudinal observational cohort study aimed at understanding the progression of Duchenne Muscular Dystrophy (DMD). The primary objective is to identify and integrate key biomarkers from multiple sources-including motor function assessments, body composition (muscle and fat distribution), clinical laboratory tests, and cardiopulmonary imaging-to delineate comprehensive disease trajectories. By analyzing how these factors change over time in a large cohort, the study seeks to develop a robust model that can identify patterns of disease progression. The ultimate goal is to generate evidence that may aid in forecasting individual patient outcomes and inform the future development of personalized rehabilitation and therapeutic strategies.

Read the detailed description

Detailed Description

  1. Comprehensive Scientific Rationale and Knowledge Gap Duchenne Muscular Dystrophy (DMD) is characterized by a highly heterogeneous disease trajectory that is not fully captured by single-domain assessments. While individual milestones of functional decline, such as loss of ambulation or decline in forced vital capacity, are well-established, the dynamic and complex interrelationships between skeletal muscle pathology, systemic fat metabolism, cardiopulmonary function, and real-world functional performance over time remain poorly quantified. This lack of a systems-level, integrated understanding of DMD progression fundamentally limits the ability of clinicians to prognosticate for individual patients, optimally time interventions, and proactively tailor rehabilitation and management plans. Existing predictive models often rely on a limited set of functional or genetic parameters, failing to fully integrate the multi-systemic, physiological remodeling that occurs as the disease evolves. The central rationale for this study is that a more robust and clinically actionable understanding of progression can be achieved by synchronously capturing and integrating high-dimensional data across multiple physiological domains. Specifically, the detailed analysis of body composition-including the progressive atrophy of specific muscle groups, the patterns of ectopic fat infiltration within muscles and organs, and shifts in visceral adipose tissue distribution-is hypothesized to contain rich information reflective of the underlying molecular pathophysiology. We posit that the simultaneous longitudinal analysis of these compositional changes, in concert with traditional functional measures and advanced cardiopulmonary imaging, will reveal novel, synergistic biomarkers of disease progression that are not apparent when these domains are studied in isolation. This study is designed to address a critical knowledge gap: the system-level mapping of how different organ systems deteriorate in relation to one another in DMD. The evidence base generated by this research is expected to be crucial for refining prognostic accuracy, informing the timely adjustment of rehabilitative strategies, and enabling sophisticated patient stratification for future clinical trials.
  2. Overall Research Strategy and Multidimensional Data Integration Framework The core innovation of this study lies not merely in the parallel collection of data, but in its sophisticated framework for integrating these multidimensional data streams to uncover their intrinsic relationships. Longitudinal Synchronization of Data Acquisition: A foundational element of the study design is the concurrent collection of all data streams (functional, compositional, imaging, laboratory) at predefined intervals throughout the study duration. This temporal alignment is critical for establishing sequence and potential causality between variables. It enables the investigation of key questions, such as whether changes in body composition precede or simply coincide with measurable declines in motor function or cardiopulmonary performance. Cross-Center Data Harmonization and Standardization: To ensure seamless data integration from multiple participating centers, the study will implement a comprehensive manual of standardized operating procedures (SOPs). These SOPs will govern every detail of all assessments and imaging protocols, encompassing patient preparation, device calibration, data acquisition, and post-processing pipelines. This rigorous quality control is a prerequisite for ensuring dataset integrity, minimizing inter-center variability, and guaranteeing that any observed differences in the final analysis reflect true biological heterogeneity rather than technical artifacts. Advanced Analytics and Modeling Methodology: Data Preprocessing and Feature Engineering: Raw data, particularly from imaging modalities, will be processed to extract quantitative, traceable features. Examples include deriving cross-sectional areas and fat fractions of specific muscle groups from magnetic resonance imaging (MRI), and calculating appendicular skeletal muscle index and fat mass index from body composition analysis. Exploratory Analysis and Hypothesis Generation: The initial analytical phase will employ exploratory data analysis techniques, including principal component analysis and unsupervised clustering algorithms, to identify naturally occurring patient subgroups within the data without a priori assumptions. This approach has the potential to uncover novel DMD phenotypes based on patterns of progression. Longitudinal Modeling: The core statistical analysis will utilize models specifically designed for repeated measures data. Mixed-effects models will be employed to quantify the intra- and inter-individual rates of change for each biomarker over time and to test associations between these rates of change and baseline covariates. Integrated Model Development and Validation: In the final phase, machine learning algorithms will be used to develop a composite model that leverages all available multimodal data to most accurately characterize disease progression trajectories. Model performance will be rigorously assessed via internal validation techniques. The primary output will be a "Disease Progression Atlas" that maps the sequence and interrelationships of multi-system physiological decline, rather than a single, simplified prognostic score.
  3. End Goals and Long-Term Impact

The ultimate output of this research is intended to be a data-driven, comprehensive atlas of DMD disease progression. This atlas will qualitatively and quantitatively describe how different physiological systems deteriorate in relation to one another, defining both common and divergent pathways of functional decline.

The anticipated findings and long-term impacts of this study include:

Deepening Pathophysiological Understanding: Elucidating the pathophysiological links between muscle composition, systemic metabolism, and functional capacity in DMD, with a specific focus on the role of ectopic fat infiltration in the progression of muscle weakness and the development of cardiopulmonary insufficiency.

Providing a Resource for Future Clinical Development: Establishing a foundational evidence base to support future clinical trials by enabling better patient stratification and identifying sensitive, multi-domain composite endpoints that may be more responsive to therapeutic interventions.

Advancing Precision Medicine: Informing the development of personalized management algorithms by clarifying which combinations of biomarkers are most informative for predicting outcomes at specific disease stages. For instance, determining whether the fat fraction of thigh muscles at a given clinical node is a more powerful predictor of ambulatory loss in the subsequent year than standard functional walk tests.

In summary, this study is designed to generate a foundational dataset that will serve as a critical resource for refining prognostic accuracy and accelerating the advancement of personalized therapeutic and rehabilitative strategies in DMD. By adopting this systematic, multimodal approach, we aim to move beyond traditional descriptive natural history studies and provide a new paradigm for understanding and managing this complex disease.

Being tested
No interventions are applied; participants are followed for natural history observation only
Keywords
Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Natural History; Multicenter Cohort Study; China; Predictive Model
Medical subject headings
Muscular Dystrophy, Duchenne, Muscular Dystrophies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No interventions are applied; participants are followed for natural history observation onlyOther

    This is an observational natural history study. No experimental interventions, treatments, or drugs are administered to participants. All data is collected through routine clinical care and follow-up assessments to document the natural progression of Duchenne and Becker Muscular Dystrophy.

Study groups in NCT07511920
Study groupRoleWhat they receive
DMD/BMD CohortSingle cohort of children with Duchenne or Becker Muscular Dystrophy
Receives: Other: No interventions are applied; participants are followed for natural history observation only

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. NorthStar Ambulatory Assessment (NSAA) score

    The NorthStar Ambulatory Assessment (NSAA) is a validated clinical scale to measure motor function in ambulatory boys with Duchenne or Becker Muscular Dystrophy.

    Measured: Baseline and 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Apr 2026
  2. Study start20 Apr 2026 (estimated)
  3. Primary completion30 Dec 2028 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07511920
Sponsor's protocol ID
2026002
Other IDs
Fund No. KL134
Acronym
WEST-DBMD
Status last verified
Mar 2026
First submitted
30 Mar 2026
Last updated
6 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Muscular Dystrophy, Becker and Muscular Dystrophy, run by West China Second University Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

NorthStar Ambulatory Assessment (NSAA) score (time frame: Baseline and 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in